Discern Health

News

W2O has bought US health economics and outcomes research company Discern Health, marking its sixth acquisition in less than a year.

News

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.